18F-FDG PET/CT代谢参数与非小细胞肺癌EGFR、ALK、KRAS突变的相关性研究进展

非小细胞肺癌（NSCLC）是一类发病率和病死率均较高的恶性肿瘤，随着对其发病机制的不断深入研究，越来越多的肺癌驱动基因被发现，针对驱动基因的分子靶向治疗也取得了显著进展。因此，明确驱动基因的突变状态在临床的治疗决策中变得尤为重要。18F-氟脱氧葡萄糖（FDG） PET/CT在NSCLC的早期诊断、分期、疗效评价及预后评估等方面具有重要价值。此外，多项研究结果表明，18F-FDG PET/CT在预测NSCLC驱动基因突变状态方面也有一定价值。笔者重点对18F-FDG PET/CT相关代谢参数与NSCLC的表皮生长因子受体、间变型淋巴瘤激酶、鼠类肉瘤病毒癌基因等驱动基因突变状态的相关性作一综述。

Research progress on the correlation between 18F-FDG PET/CT metabolic parameters and mutations of EGFR,ALK and KRAS in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a malignant tumor with high morbidity and mortality. Considering the number of in-depth studies on its pathogenesis, the number of lung cancer driver genes that have been discovered is increasing. Molecular targeted therapy for driver genes has also made significant progress. Therefore, clarifying the mutation status of the driver gene in clinical treatment decisions is particularly important. 18F-fluorodeoxyglucose(FDG) PET/CT plays an important role in the early diagnosis, staging, efficacy evaluation, and prognosis evaluation of NSCLC. 18F-FDG PET/CT is valuable in predicting the mutation status of driver genes in NSCLC. This review focuses on the correlation between 18F-FDG PET/CT related metabolic parameters and the mutation status of epidermal growth factor receptor, anaplastic lymphoma kinase, kirsten rate sarcoma viral oncogene homolog, and other driver genes in NSCLC.